The present invention discloses a new therapeutic composition ND-100 for intra-peritoneal use and consisting of the compound NQDI-1 (ethyl 2, 7-dioxo-2, 7-dihydro-3H-naphtho [1, 2, 3-de]quinoline-1-carboxylate in solution form, in a specific quantity for the treatment and prevention of Alzheimers disease and other neuro-degenerative disorders. The compound has structure as given. The therapeutic composition is described in terms of safety, efficacy, dose and route of dministration. For human use, the prescribed dose is 0.0000405mg/kg or 0.0405 microgram/kg body weight to be injected intraperitoneally over a period of time, till relief and recovery from disease. As a preventive drug, the same if injected at regular intervals or taken orally can prevent neurodegeneration and ensure quality of life for senior patients. Oral formulation can be made as per bio-availability data of the compound which can be easily worked out.
THAKUR GURJEET SINGH, AVANEESH KUMAR, SONIA DHIMAN, PARAMDEEP SINGH, MAYANK SIPPY